1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Clinical Psychology
  4. Volume 17, 2021
  5. Article

Annual Review of Clinical Psychology

Volume 17, 2021

Smoking Treatment: A Report Card on Progress and Challenges

Abstract

The impact of tobacco smoking treatment is determined by its reach into the smoking population and the effectiveness of its interventions. This review evaluates the reach and effectiveness of pharmacotherapy and psychosocial interventions for smoking. Historically, the reach of smoking treatment has been low, and therefore its impact has been limited, but new reach strategies such as digital interventions and health care system changes offer great promise. Pharmacotherapy tends to be more effective than psychosocial intervention when used clinically, and newer pharmacotherapy strategies hold great promise of further enhancing effectiveness. However, new approaches are needed to advance psychosocial interventions; progress has stagnated because research and dissemination efforts have focused too narrowly on skill training despite evidence that its core content may be inconsequential and the fact that its mechanisms are either unknown or inconsistent with supporting theory. Identifying effective psychosocial content and its mechanisms of action could greatly enhance the effectiveness of counseling, digital, and web interventions.

Keyword(s): smoking cessation, smoking pharmacotherapy, smoking treatment, smoking treatment effectiveness
Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-081219-090343
2021-05-07
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/17/1/annurev-clinpsy-081219-090343.html?itemId=/content/journals/10.1146/annurev-clinpsy-081219-090343&mimeType=html&fmt=ahah

Literature Cited

  1. Adsit RT, Fox BM, Tsiolis T, Ogland C, Simerson M et al. 2014. Using the electronic health record to connect primary care patients to evidence-based telephonic tobacco quitline services: a closed-loop demonstration project. Trans. Behav. Med. 4:3324–32 https://doi.org/10.1007/s13142-014-0259-y
    [Crossref] [Google Scholar]
  2. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T et al. 2016. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387:100372507–20 https://doi.org/10.1016/S0140-6736(16)30272-0
    [Crossref] [Google Scholar]
  3. Augustson E, Engelgau MM, Zhang S, Cai Y, Cher W et al. 2017. Text to Quit China: an mHealth smoking cessation trial. Am. J. Health Promot. 31:3217–25 https://doi.org/10.4278/ajhp.140812-QUAN-399
    [Crossref] [Google Scholar]
  4. Baker TB. 2017. The 2016 Ferno Award address: three things. Nicotine Tob. Res. 19:8891–900 https://doi.org/10.1093/ntr/ntx039
    [Crossref] [Google Scholar]
  5. Baker TB, Berg KM, Adsit RT, Skora AD, Swedlund MP et al. 2021. Closed loop electronic referral from primary care clinics to a state tobacco cessation quitline: effects using real-world implementation training. Am. J. Prev. Med 60:Suppl. 2S113–22
     [Google Scholar]
  6. Baker TB, Fraser DL, Kobinsky K, Adsit R, Smith SS et al. 2018. A randomized controlled trial of financial incentives to low income pregnant women to engage in smoking cessation treatment: effects on post-birth abstinence. J. Consult. Clin. Psychol. 86:5464–73 https://doi.org/10.1037/ccp0000278
    [Crossref] [Google Scholar]
  7. Baker TB, Mermelstein R, Collins LM, Piper ME, Jorenby DE et al. 2011. New methods for tobacco dependence treatment research. Ann. Behav. Med. 41:2192–207 https://doi.org/10.1007/s12160-010-9252-y
    [Crossref] [Google Scholar]
  8. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. 2004. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol. Rev. 111:133–51 https://doi.org/10.1037/0033-295X.111.1.33
    [Crossref] [Google Scholar]
  9. Bansal MA, Cummings KM, Hyland A, Giovino GA. 2004. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them?. Nicotine Tob. Res. 6:Suppl. 3S303–10 https://doi.org/10.1080/14622200412331320707
    [Crossref] [Google Scholar]
  10. Bao Y, Duan N, Fox SA. 2006. Is some provider advice on smoking cessation better than no advice? An instrumental variable analysis of the 2001 National Health Interview Survey. Health Serv. Res. 41:62114–35
     [Google Scholar]
  11. Barber JP, Connolly MB, Crits-Christoph P, Gladis L, Siqueland L 2000. Alliance predicts patients' outcome beyond in-treatment change in symptoms. J. Consult. Clin. Psychol. 68:61027–32 https://doi.org/10.1037/0022-006x.68.6.1027
    [Crossref] [Google Scholar]
  12. Bechara A, Berridge KC, Bickel WK, Moron JA, Williams SB, Stein JS. 2019. A neurobehavioral approach to addiction: implications for the opioid epidemic and the psychology of addiction. Psychol. Sci. Public Interest 20:296–127 https://doi.org/10.1177/1529100619860513
    [Crossref] [Google Scholar]
  13. Belsky DW, Moffitt TE, Baker TB, Biddle AK, Evans JP et al. 2013. Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence: evidence from a 4-decade longitudinal study. JAMA Psychiatry 70:5534–42 https://doi.org/10.1001/jamapsychiatry.2013.736
    [Crossref] [Google Scholar]
  14. Bohadana A, Freier-Dror Y, Peles V, Babai P, Izbicki G 2020. Extending varenicline preloading to 6 weeks facilitates smoking cessation: a single-site, randomised controlled trial. EClinicalMedicine 19:100228 https://doi.org/10.1016/j.eclinm.2019.11.021
    [Crossref] [Google Scholar]
  15. Bolt DM, Piper ME, Theobald WE, Baker TB 2012. Why two smoking cessation agents work better than one: role of craving suppression. J. Consult. Clin. Psychol. 80:154–65 https://doi.org/10.1037/a0026366
    [Crossref] [Google Scholar]
  16. Borland R, Partos TR, Cummings KM. 2012. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob. Res. 14:121483–87 https://doi.org/10.1093/ntr/nts002
    [Crossref] [Google Scholar]
  17. Borrelli B, Bartlett YK, Tooley E, Armitage CJ, Wearden A. 2015. Prevalence and frequency of mHealth and eHealth use among US and UK smokers and differences by motivation to quit. J. Med. Internet Res. 17:7e164 https://doi.org/10.2196/jmir.4420
    [Crossref] [Google Scholar]
  18. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA et al. 2011. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology 218:391–403
     [Google Scholar]
  19. Brandon TH, Tiffany ST, Obremski KM, Baker TB. 1990. Postcessation cigarette use: the process of relapse. Addict. Behav. 15:2105–14 https://doi.org/10.1016/0306-4603(90)90013-n
    [Crossref] [Google Scholar]
  20. Bricker JB, Mann SL, Marek PM, Liu J, Peterson AV. 2010. Telephone-delivered Acceptance and Commitment Therapy for adult smoking cessation: a feasibility study. Nicotine Tob. Res. 12:4454–58 https://doi.org/10.1093/ntr/ntq002
    [Crossref] [Google Scholar]
  21. Bricker JB, Mull KE, McClure JB, Watson NL, Heffner JL. 2018. Improving quit rates of web-delivered interventions for smoking cessation: full-scale randomized trial of WebQuit.org versus Smokefree.gov. Addiction 113:5914–23 https://doi.org/10.1111/add.14127
    [Crossref] [Google Scholar]
  22. Bricker JB, Watson NL, Mull KE, Sullivan BM, Heffner JL. 2020. Efficacy of smartphone applications for smoking cessation: a randomized clinical trial. JAMA Intern. Med. 180:111472–80 https://doi.org/10.1001/jamainternmed.2020.4055
    [Crossref] [Google Scholar]
  23. Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E et al. 2007. Neural substrates of resisting craving during cigarette cue exposure. Biol. Psychiatry 62:6642–51 https://doi.org/10.1016/j.biopsych.2006.10.026
    [Crossref] [Google Scholar]
  24. Brown J, Michie S, Geraghty AWA, Yardley L, Gardner B et al. 2014. Internet-based intervention for smoking cessation (StopAdvisor) in people with low and high socioeconomic status: a randomised controlled trial. Lancet Respir. Med. 2:12997–1006
     [Google Scholar]
  25. Brown RA, Palm Reed KM, Bloom EL, Minami H, Strong DR et al. 2018. A randomized controlled trial of distress tolerance treatment for smoking cessation. Psychol. Addict. Behav. 32:4389–400 https://doi.org/10.1037/adb0000372
    [Crossref] [Google Scholar]
  26. Cahill K, Hartmann-Boyce J, Perera R. 2015. Incentives for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD004307.pub5
    [Crossref] [Google Scholar]
  27. Campaign for Tobacco-Free Kids 2017. Quitlines help smokers quit. Fact sheet, Campaign for Tobacco-Free Kids Washington, DC: https://www.tobaccofreekids.org/assets/factsheets/0326.pdf
    [Google Scholar]
  28. Cantrell J, Shelley D. 2009. Implementing a fax referral program for quitline smoking cessation services in urban health centers: a qualitative study. BMC Fam. Pract. 10:81 https://doi.org/10.1186/1471-2296-10-81
    [Crossref] [Google Scholar]
  29. Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA. 2017. Quit methods used by US adult cigarette smokers, 2014–2016. Prev. Chronic Dis. 14:160600 https://doi.org/10.5888/pcd14.160600
    [Crossref] [Google Scholar]
  30. Carpenter MJ, Wahlquist AE, Dahne J, Gray KM, Garrett-Mayer E et al. 2020. Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial. Addiction 115:71358–67
     [Google Scholar]
  31. Carter BL, Tiffany ST 1999. Meta-analysis of cue-reactivity in addiction research. Addiction 94:3327–40
     [Google Scholar]
  32. Chaney EF, O'Leary MR, Marlatt GA 1978. Skill training with alcoholics. J. Consult. Clin. Psychol. 46:51092–104 https://doi.org/10.1037/0022-006x.46.5.1092
    [Crossref] [Google Scholar]
  33. Chen LS, Baker TB, Miller JP, Bray M, Smock N et al. 2020. Comparing varenicline and combination nicotine replacement therapy with placebo: support for genetically informed smoking cessation. Lancet Respir. Med. In press
    [Google Scholar]
  34. Chenoweth MJ, Schnoll RA, Novalen M, Hawk LW Jr., George TP et al. 2016. The nicotine metabolite ratio is associated with early smoking abstinence even after controlling for factors that influence the nicotine metabolite ratio. Nicotine Tob. Res. 18:4491–95 https://doi.org/10.1093/ntr/ntv125
    [Crossref] [Google Scholar]
  35. Ciccocioppo R, Angeletti S, Weiss F. 2001. Long-lasting resistance to extinction of response reinstatement induced by ethanol-related stimuli: role of genetic ethanol preference. Alcohol. Clin. Exp. Res. 25:101414–19 https://doi.org/10.1097/00000374-200110000-00002
    [Crossref] [Google Scholar]
  36. Cokkinides VE, Ward E, Jemal A, Thun MJ. 2005. Under-use of smoking-cessation treatments: results from the National Health Interview Survey; 2000. Am. J. Prev. Med. 28:1119–22 https://doi.org/10.1016/j.amepre.2004.09.007
    [Crossref] [Google Scholar]
  37. Cook JW, Collins LM, Fiore MC, Smith SS, Fraser D et al. 2016. Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment. Addiction 111:1117–28 https://doi.org/10.1111/add.13161
    [Crossref] [Google Scholar]
  38. Cook JW, Lanza ST, Chu W, Baker TB, Piper ME. 2017. Anhedonia: its dynamic relations with craving, negative affect, and treatment during a quit smoking attempt. Nicotine Tob. Res. 19:6703–9 https://doi.org/10.1093/ntr/ntw247
    [Crossref] [Google Scholar]
  39. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. 1997. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 278:211759–66
     [Google Scholar]
  40. Cropsey KL, Hendricks PS, Schiavon S, Sellers A, Froelich M et al. 2017. A pilot trial of in vivo NRT sampling to increase medication adherence in community corrections smokers. Addict. Behav. 67:92–99 https://doi.org/10.1016/j.addbeh.2016.12.011
    [Crossref] [Google Scholar]
  41. Digiusto E, Bird KD. 1995. Matching smokers to treatment: self-control versus social support. J. Consult. Clin. Psychol. 63:2290–95
     [Google Scholar]
  42. Do HP, Tran BX, Le Pham Q, Nguyen LH, Tran TT et al. 2018. Which eHealth interventions are most effective for smoking cessation? A systematic review. Patient Preference Adherence 12:2065–84 https://doi.org/10.2147/PPA.S169397
    [Crossref] [Google Scholar]
  43. Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL et al. 2015. Randomized trial of reduced-nicotine standards for cigarettes. N. Engl. J. Med. 373:141340–49 https://doi.org/10.1056/NEJMsa1502403
    [Crossref] [Google Scholar]
  44. Drobes DJ, Meier EA, Tiffany ST 1994. Assessment of the effects of urges and negative affect on smokers' coping skills. Behav. Res. Ther. 32:1165–74 https://doi.org/10.1016/0005-7967(94)90099-x
    [Crossref] [Google Scholar]
  45. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C et al. 2015. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 313:7687–94 https://doi.org/10.1001/jama.2015.280
    [Crossref] [Google Scholar]
  46. Ellerbeck EF, Mahnken JD, Cupertino AP, Cox LS, Greiner KA et al. 2009. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann. Intern. Med. 150:7437–46
     [Google Scholar]
  47. Fedota JR, Sutherland MT, Salmeron BJ, Ross TJ, Hong LE, Stein EA. 2015. Reward anticipation is differentially modulated by varenicline and nicotine in smokers. Neuropsychopharmacology 40:2038–46
     [Google Scholar]
  48. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. 2005. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 8:3178–90
     [Google Scholar]
  49. Ferguson SG, Shiffman S. 2009. The relevance and treatment of cue-induced cravings in tobacco dependence. J. Subst. Abuse Treat. 36:3235–43
     [Google Scholar]
  50. Ferguson SG, Shiffman S, Gwaltney CJ. 2006. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J. Consult. Clin. Psychol. 74:61153–61 https://doi.org/10.1037/0022-006X.74.6.1153
    [Crossref] [Google Scholar]
  51. Fiore M, Adsit R, Zehner M, McCarthy D, Lundsten S et al. 2019. An electronic health record–based interoperable eReferral system to enhance smoking quitline treatment in primary care. J. Am. Med. Inform. Assoc. 26:8–9778–86 https://doi.org/10.1093/jamia/ocz044
    [Crossref] [Google Scholar]
  52. Fiore MC, Baker TB. 2021. Ten million calls and counting: progress and promise of tobacco quitlines in the U.S. Am. J. Prev. Med 60:3S103–6
     [Google Scholar]
  53. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N et al. 2008. Treating Tobacco Use and Dependence: 2008 Update Rockville, MD: US Dep. Health Hum. Serv., US Public Health Serv.
  54. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J et al. 2011. Effects of varenicline on smoking cue–triggered neural and craving responses. Arch. Gen. Psychiatry 68:516–26
     [Google Scholar]
  55. Fraser DL, Fiore MC, Kobinsky K, Adsit R, Smith SS et al. 2017. A randomized trial of incentives for smoking treatment in Medicaid members. Am. J. Prev. Med. 53:6754–63 https://doi.org/10.1016/j.amepre.2017.08.027
    [Crossref] [Google Scholar]
  56. Free C, Knight R, Robertson S, Whittaker R, Edwards P et al. 2011. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 378:978549–55 https://doi.org/10.1016/S0140-6736(11)60701-0
    [Crossref] [Google Scholar]
  57. Glatard A, Dobrinas M, Gholamrezaee M, Lubomirov R, Cornuz J et al. 2017. Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. Exp. Clin. Psychopharmacol. 25:5353–62 https://doi.org/10.1037/pha0000141
    [Crossref] [Google Scholar]
  58. Graham AL, Cobb NK, Papandonatos GD, Moreno JL, Kang H et al. 2011. A randomized trial of internet and telephone treatment for smoking cessation. Arch. Intern. Med. 171:146–53 Erratum. 2011. Arch. Intern. Med. 171(5):395
    [Google Scholar]
  59. Graham AL, Papandonatos GD, Jacobs MA, Amato MS, Cha S et al. 2020. Optimizing text messages to promote engagement with internet smoking cessation treatment: results from a factorial screening experiment. J. Med. Internet Res. 22:4e17734 https://doi.org/10.2196/17734
    [Crossref] [Google Scholar]
  60. Hammett E, Veldheer S, Hrabovsky S, Yingst J, Berg A et al. 2018. TXT2STAYQUIT: pilot randomized trial of brief automated smoking cessation texting intervention for inpatient smokers discharged from the hospital. J. Hosp. Med. 13:7488–89 https://doi.org/10.12788/jhm.2907
    [Crossref] [Google Scholar]
  61. Harrington KF, Kim Y-I, Chen M, Ramachandran R, Pisu M et al. 2016. Web-based intervention for transitioning smokers from inpatient to outpatient care: an RCT. Am. J. Prev. Med. 51:4620–29
     [Google Scholar]
  62. Hayes SC, Strosahl K, Wilson K 1999. Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change New York: Guilford
  63. Heckman BW, Dahne J, Germeroth LJ, Mathew AR, Santa Ana EJ et al. 2018. Does cessation fatigue predict smoking-cessation milestones? A longitudinal study of current and former smokers. J. Consult. Clin. Psychol. 86:11903–14 https://doi.org/10.1037/ccp0000338
    [Crossref] [Google Scholar]
  64. Hendershot CS, Witkiewitz K, George WH, Marlatt GA. 2011. Relapse prevention for addictive behaviors. Subst. Abuse Treat. Prev. Policy 6:17 https://doi.org/10.1186/1747-597X-6-17
    [Crossref] [Google Scholar]
  65. Holtrop JS, Malouin R, Weismantel D, Wadland WC. 2008. Clinician perceptions of factors influencing referrals to a smoking cessation program. BMC Fam. Pract. 9:18 https://doi.org/10.1186/1471-2296-9-18
    [Crossref] [Google Scholar]
  66. Hughes JR, Shiffman S, Callas P, Zhang J. 2003. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob. Control 12:121–27
     [Google Scholar]
  67. Humfleet GL, Hall SM, Delucchi KL, Dilley JW. 2013. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob. Res 15:81436–45
     [Google Scholar]
  68. Japuntich SJ, Zehner ME, Smith SS, Jorenby DE, Valdez JA et al. 2006. Smoking cessation via the internet: a randomized clinical trial of an internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob. Res. 8:Suppl. 1S59–67
     [Google Scholar]
  69. Johnson SL, Elliott MV, Carver CS. 2020. Impulsive responses to positive and negative emotions: parallel neurocognitive correlates and their implications. Biol. Psychiatry 87:4338–49 https://doi.org/10.1016/j.biopsych.2019.08.018
    [Crossref] [Google Scholar]
  70. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP et al. 1995. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274:171347–52
     [Google Scholar]
  71. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M et al. 2011. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch. Intern. Med. 171:211894–900 https://doi.org/10.1001/archinternmed.2011.500
    [Crossref] [Google Scholar]
  72. Kahende J, Malarcher A, England L, Zhang L, Mowery P et al. 2017. Utilization of smoking cessation medication benefits among Medicaid fee-for-service enrollees 1999–2008. PLOS ONE 12:2e0170381 https://doi.org/10.1371/journal.pone.0170381
    [Crossref] [Google Scholar]
  73. Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M et al. 2013. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 108:1193–202 https://doi.org/10.1111/j.1360-0443.2012.04009.x
    [Crossref] [Google Scholar]
  74. Kaufmann A, Hitsman B, Goelz PM, Veluz-Wilkins A, Blazekovic S et al. 2015. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Addict. Behav. 51:93–99 https://doi.org/10.1016/j.addbeh.2015.07.019
    [Crossref] [Google Scholar]
  75. Killen JD, Fortmann SP, Murphy GM Jr., Hayward C, Arredondo C et al. 2006. Extended treatment with bupropion SR for cigarette smoking cessation. J. Consult. Clin. Psychol. 74:2286–94
     [Google Scholar]
  76. Kim N, McCarthy DE, Loh W-Y, Cook JW, Piper ME et al. 2019. Predictors of adherence to nicotine replacement therapy: machine learning evidence that perceived need predicts medication use. Drug Alcohol Depend 205:107668
     [Google Scholar]
  77. Kober H, Kross EF, Mischel W, Hart CL, Ochsner KN. 2010. Regulation of craving by cognitive strategies in cigarette smokers. Drug Alcohol Depend 106:152–55 https://doi.org/10.1016/j.drugalcdep.2009.07.017
    [Crossref] [Google Scholar]
  78. Kotz D, Brown J, West R. 2014a. Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. Psychopharmacology 231:137–42 https://doi.org/10.1007/s00213-013-3202-x
    [Crossref] [Google Scholar]
  79. Kotz D, Brown J, West R. 2014b.. ‘ Real-world’ effectiveness of smoking cessation treatments: a population study. Addiction 109:3491–99 https://doi.org/10.1111/add.12429
    [Crossref] [Google Scholar]
  80. Kouimtsidis C, Stahl D, West R, Drummond C. 2016. Path analysis of cognitive behavioral models in smoking: What is the relationship between concepts involved?. J. Subst. Use 21:5553–57
     [Google Scholar]
  81. Krupski L, Cummings KM, Hyland A, Mahoney MC, Toll BA et al. 2016. Cost and effectiveness of combination nicotine replacement therapy among heavy smokers contacting a quitline. J. Smoking Cessat. 11:150–59
     [Google Scholar]
  82. Lam CY, Businelle MS, Aigner CJ, McClure JB, Cofta-Woerpel L et al. 2014. Individual and combined effects of multiple high-risk triggers on postcessation smoking urge and lapse. Nicotine Tob. Res. 16:5569–75 https://doi.org/10.1093/ntr/ntt190
    [Crossref] [Google Scholar]
  83. Lancaster T, Stead LF. 2017. Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD001292.pub3
    [Crossref] [Google Scholar]
  84. Leas EC, Pierce JP, Benmarhnia T, White MM, Noble ML et al. 2018. Effectiveness of pharmaceutical smoking cessation aids in a nationally representative cohort of American smokers. J. Natl. Cancer Inst. 110:6581–87 https://doi.org/10.1093/jnci/djx240
    [Crossref] [Google Scholar]
  85. Lee EB, An W, Levin ME, Twohig MP 2015. An initial meta-analysis of Acceptance and Commitment Therapy for treating substance use disorders. Drug Alcohol Depend 155:1–7 https://doi.org/10.1016/j.drugalcdep.2015.08.004
    [Crossref] [Google Scholar]
  86. Lerman C, Schnoll RA, Hawk LW Jr., Cinciripini P, George TP et al. 2015. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 3:2131–38 https://doi.org/10.1016/S2213-2600(14)70294-2
    [Crossref] [Google Scholar]
  87. Levin M, Hayes SC. 2009. Is Acceptance and Commitment Therapy superior to established treatment comparisons?. Psychother. Psychosom. 78:6380 https://doi.org/10.1159/000235978
    [Crossref] [Google Scholar]
  88. Linder JA, Kaleba EO, Kmetik KS. 2009. Using electronic health records to measure physician performance for acute conditions in primary care: empirical evaluation of the community-acquired pneumonia clinical quality measure set. Med. Care 47:2208–16 https://doi.org/10.1097/MLR.0b013e318189375f
    [Crossref] [Google Scholar]
  89. Lindson N, Aveyard P. 2011. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology 214:3579–92 https://doi.org/10.1007/s00213-010-2069-3
    [Crossref] [Google Scholar]
  90. Lindson N, Thompson TP, Ferrey A, Lambert JD, Aveyard P. 2019. Motivational Interviewing for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD006936.pub4
    [Crossref] [Google Scholar]
  91. Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Hajek P 2019. Relapse prevention interventions for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD003999.pub5
    [Crossref] [Google Scholar]
  92. Lu W, Chappell K, Walters JAE, Jacobson GA, Patel R et al. 2017. The effect of varenicline and nicotine patch on smoking rate and satisfaction with smoking: an examination of the mechanism of action of two pre-quit pharmacotherapies. Psychopharmacology 234:1969–76
     [Google Scholar]
  93. Maciosek MV, Armour BS, Babb SD, Dhemer SP, Grossman ES et al. 2020. Budgetary impact from multiple perspectives of sustained antitobacco national media campaigns to reduce the harms of cigarette smoking. Tob. Control In press. https://doi.org/10.1136/tobaccocontrol-2019-055482
    [Crossref] [Google Scholar]
  94. Maglione MA, Maher AR, Ewing B, Colaiaco B, Newberry S et al. 2017. Efficacy of mindfulness meditation for smoking cessation: a systematic review and meta-analysis. Addict. Behav. 69:27–34 https://doi.org/10.1016/j.addbeh.2017.01.022
    [Crossref] [Google Scholar]
  95. McAfee TA, Bush T, Deprey TM, Mahoney LD, Zbikowski SM et al. 2008. Nicotine patches and uninsured quitline callers: a randomized trial of two versus eight weeks. Am. J. Prev. Med. 35:2103–10 https://doi.org/10.1016/j.amepre.2008.04.017
    [Crossref] [Google Scholar]
  96. McAfee TA, Davis KC, Alexander RL Jr, Pechacek TF, Bunnell R 2013. Effect of the first federally funded US antismoking national media campaign. Lancet 382:99092003–11 https://doi.org/10.1016/S0140-6736(13)61686-4
    [Crossref] [Google Scholar]
  97. McCallion EA, Zvolensky MJ. 2015. Acceptance and Commitment Therapy (ACT) for smoking cessation: a synthesis. Curr. Opin. Psychol. 2:47–51
     [Google Scholar]
  98. McCarthy DE, Piasecki TM, Jorenby DE, Lawrence DL, Shiffman S, Baker TB. 2010. A multi-level analysis of non-significant counseling effects in a randomized smoking cessation trial. Addiction 105:122195–208 https://doi.org/10.1111/j.1360-0443.2010.03089.x
    [Crossref] [Google Scholar]
  99. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S et al. 2008. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob. Res. 10:4717–29 https://doi.org/10.1080/14622200801968343
    [Crossref] [Google Scholar]
  100. McClure JB, Bricker J, Mull K, Heffner JL. 2020. Comparative effectiveness of group-delivered acceptance and commitment therapy versus cognitive behavioral therapy for smoking cessation: a randomized controlled trial. Nicotine Tob. Res. 22:3354–62 https://doi.org/10.1093/ntr/nty268
    [Crossref] [Google Scholar]
  101. McClure JB, Peterson D, Derry H, Riggs K, Saint-Johnson J et al. 2014. Exploring the “active ingredients” of an online smoking intervention: a randomized factorial trial. Nicotine Tob. Res. 16:81129–39 https://doi.org/10.1093/ntr/ntu057
    [Crossref] [Google Scholar]
  102. McDonnell DD, Kazinets G, Lee H-J, Moskowitz JM. 2011. An internet-based smoking cessation program for Korean Americans: results from a randomized controlled trial. Nicotine Tob. Res. 13:5336–43
     [Google Scholar]
  103. Menon J, Kandasamy A. 2018. Relapse prevention. Indian J. Psychiatry 60:Suppl. 2S473–78
     [Google Scholar]
  104. Mermelstein R, Hedeker D, Wong S-C. 2003. Extended telephone counseling for smoking cessation: Does content matter?. J. Consult. Clin. Psychol. 71:3565–74
     [Google Scholar]
  105. Miller CL, Sedivy V. 2009. Using a quitline plus low-cost nicotine replacement therapy to help disadvantaged smokers to quit. Tob. Control 18:2144–49 https://doi.org/10.1136/tc.2008.026492
    [Crossref] [Google Scholar]
  106. Moller AC, Merchant G, Conroy DE, West R, Hekler E et al. 2017. Applying and advancing behavior change theories and techniques in the context of a digital health revolution: proposals for more effectively realizing untapped potential. J. Behav. Med. 40:185–98 https://doi.org/10.1007/s10865-016-9818-7
    [Crossref] [Google Scholar]
  107. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. 2009. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 338:b1024 https://doi.org/10.1136/bmj.b1024
    [Crossref] [Google Scholar]
  108. Mundt MP, Baker TB, Fraser DL, Smith SS, Piper ME, Fiore MC. 2019. Paying low-income smokers to quit? The cost-effectiveness of incentivizing tobacco quit line engagement for Medicaid recipients who smoke. Value Health 22:2177–84 https://doi.org/10.1016/j.jval.2018.08.001
    [Crossref] [Google Scholar]
  109. Murphy-Hoefer R, Davis KC, Beistle D, King BA, Duke J et al. 2018. Impact of the Tips From Former Smokers campaign on population-level smoking cessation, 2012–2015. Prev. Chronic Dis. 15:180051 https://doi.org/10.5888/pcd15.180051
    [Crossref] [Google Scholar]
  110. Neidigh LW, Gesten EL, Shiffman S. 1988. Coping with the temptation to drink. Addict. Behav. 13:11–9 https://doi.org/10.1016/0306-4603(88)90019-6
    [Crossref] [Google Scholar]
  111. Perry CJ, Zbukvic I, Kim JH, Lawrence AJ. 2014. Role of cues and contexts on drug-seeking behaviour. Br. J. Pharmacol. 171:204636–72 https://doi.org/10.1111/bph.12735
    [Crossref] [Google Scholar]
  112. Piasecki TM, Fiore MC, McCarthy DE, Baker TB. 2002. Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction 97:91093–108
     [Google Scholar]
  113. Pierce JP, Gilpin EA. 2002. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 288:101260–64
     [Google Scholar]
  114. Piper ME, Fiore MC, Smith SS, Fraser D, Bolt DM et al. 2016. Identifying effective intervention components for smoking cessation: a factorial screening experiment. Addiction 111:1129–41 https://doi.org/10.1111/add.13162
    [Crossref] [Google Scholar]
  115. Rabius V, Pike KJ, Wiatrek D, McAlister AL. 2008. Comparing internet assistance for smoking cessation: 13-month followup of a six-arm randomized controlled trial. J. Med. Internet Res 10:5e45
     [Google Scholar]
  116. Richter KP, Ellerbeck EF. 2015. It's time to change the default for tobacco treatment. Addiction 110:3381–86 https://doi.org/10.1111/add.12734
    [Crossref] [Google Scholar]
  117. Richter KP, Faseru B, Shireman TI, Mussulman LM, Nazir N et al. 2016. Warm handoff versus fax referral for linking hospitalized smokers to quitlines. Am. J. Prev. Med. 51:4587–96 https://doi.org/10.1016/j.amepre.2016.04.006
    [Crossref] [Google Scholar]
  118. Robinson TE, Berridge KC. 2008. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. B 363: 1507.3137–46 https://doi.org/10.1098/rstb.2008.0093
    [Crossref] [Google Scholar]
  119. Roddy E, Antoniak M, Britton J, Molyneux A, Lewis S. 2006. Barriers and motivators to gaining access to smoking cessation services amongst deprived smokers—a qualitative study. BMC Health Serv. Res. 6:147 https://doi.org/10.1186/1472-6963-6-147
    [Crossref] [Google Scholar]
  120. Rogers ES, Fu SS, Krebs P, Noorbaloochi S, Nugent SM et al. 2018. Proactive tobacco treatment for smokers using Veterans Administration mental health clinics. Am. J. Prev. Med. 54:5620–29 https://doi.org/10.1016/j.amepre.2018.02.011
    [Crossref] [Google Scholar]
  121. Rogojanski J, Vettese LC, Antony MM 2011. Role of sensitivity to anxiety symptoms in responsiveness to mindfulness versus suppression strategies for coping with smoking cravings. J. Clin. Psychol. 67:4439–45 https://doi.org/10.1002/jclp.20774
    [Crossref] [Google Scholar]
  122. Sayette MA. 2016. The role of craving in substance use disorders: theoretical and methodological issues. Annu. Rev. Clin. Psychol. 12:407–33 https://doi.org/10.1146/annurev-clinpsy-021815-093351
    [Crossref] [Google Scholar]
  123. Sayette MA, Creswell KG 2016. Self-regulatory failure and addiction. Handbook of Self-Regulation: Research, Theory, and Applications KD Vohs, RF Baumeister 571–90 New York: Guilford. , 3rd ed..
     [Google Scholar]
  124. Sayette MA, Loewenstein G, Griffin KM, Black JJ. 2008. Exploring the cold-to-hot empathy gap in smokers. Psychol. Sci. 19:9926–32 https://doi.org/10.1111/j.1467-9280.2008.02178.x
    [Crossref] [Google Scholar]
  125. Schassburger RL, Levin ME, Weaver MT, Palmatier MI, Caggiula AR et al. 2015. Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline. . Psychopharmacology 232:5975–83
     [Google Scholar]
  126. Schauer GL, Malarcher AM, Zhang L, Engstrom MC, Zhu SH. 2014. Prevalence and correlates of quitline awareness and utilization in the United States: an update from the 2009–2010 National Adult Tobacco Survey. Nicotine Tob. Res. 16:5544–53 https://doi.org/10.1093/ntr/ntt181
    [Crossref] [Google Scholar]
  127. Schlam TR, Baker TB. 2020. Playing around with quitting smoking: a randomized pilot trial of mobile games as a craving response strategy. Games Health J 9:164–70 https://doi.org/10.1089/g4h.2019.0030
    [Crossref] [Google Scholar]
  128. Schlam TR, Baker TB, Smith SS, Bolt DM, McCarthy DE et al. 2020. Electronically monitored nicotine gum use before and after smoking lapses: relationship with lapse and relapse. Nicotine Tob. Res. 22:112051–58 https://doi.org/10.1093/ntr/ntaa116
    [Crossref] [Google Scholar]
  129. Schlam TR, Cook JW, Baker TB, Hayes-Birchler T, Bolt DM et al. 2018. Can we increase smokers' adherence to nicotine replacement therapy and does this help them quit?. Psychopharmacology 235:72065–75 https://doi.org/10.1007/s00213-018-4903-y
    [Crossref] [Google Scholar]
  130. Schlam TR, Fiore MC, Smith SS, Fraser D, Bolt DM et al. 2016. Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment. Addiction 111:1142–55 https://doi.org/10.1111/add.13153
    [Crossref] [Google Scholar]
  131. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L et al. 2015. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern. Med. 175:4504–11 https://doi.org/10.1001/jamainternmed.2014.8313
    [Crossref] [Google Scholar]
  132. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. 2009. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 92:16–11 https://doi.org/10.1016/j.pbb.2008.10.016
    [Crossref] [Google Scholar]
  133. Schuck K, Otten R, Kleinjan M, Bricker JB, Engels RC. 2014. Self-efficacy and acceptance of cravings to smoke underlie the effectiveness of quitline counseling for smoking cessation. Drug Alcohol Depend 142:269–76 https://doi.org/10.1016/j.drugalcdep.2014.06.033
    [Crossref] [Google Scholar]
  134. Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP. 2017. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD011823.pub2
    [Crossref] [Google Scholar]
  135. Shahab L, Bauld L, McNeill A, Tyndale RF. 2019. Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. Addiction 114:2304–14 https://doi.org/10.1111/add.14450
    [Crossref] [Google Scholar]
  136. Shaham Y, Erb S, Stewart J. 2000. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res. Rev. 33:113–33 https://doi.org/10.1016/s0165-0173(00)00024-2
    [Crossref] [Google Scholar]
  137. Shiffman S. 1986. A cluster-analytic classification of smoking relapse episodes. Addict. Behav. 11:3295–307 https://doi.org/10.1016/0306-4603(86)90057-2
    [Crossref] [Google Scholar]
  138. Shiffman S, Dunbar M, Kirchner T, Li X, Tindle H et al. 2013. Smoker reactivity to cues: effects on craving and on smoking behavior. J. Abnorm. Psychol. 122:1264–80 https://doi.org/10.1037/a0028339
    [Crossref] [Google Scholar]
  139. Shiffman S, Li X, Dunbar MS, Tindle HA, Scholl SM, Ferguson SG. 2015. Does laboratory cue reactivity correlate with real-world craving and smoking responses to cues?. Drug Alcohol Depend 155:163–69 https://doi.org/10.1016/j.drugalcdep.2015.07.673
    [Crossref] [Google Scholar]
  140. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. 1996. First lapses to smoking: within-subjects analysis of real-time reports. J. Consult. Clin. Psychol. 64:2366–79 https://doi.org/10.1037//0022-006x.64.2.366
    [Crossref] [Google Scholar]
  141. Silver L. 2020. Smartphone ownership is growing rapidly around the world, but not always equally. Pew Research Center https://www.pewresearch.org/global/2019/02/05/smartphone-ownership-is-growing-rapidly-around-the-world-but-not-always-equally/
    [Google Scholar]
  142. Skov-Ettrup LS, Dalum P, Bech M, Tolstrup JS. 2016. The effectiveness of telephone counselling and internet- and text-message-based support for smoking cessation: results from a randomized controlled trial. Addiction 111:71257–66
     [Google Scholar]
  143. Smith SS, Keller PA, Kobinsky KH, Baker TB, Fraser DL et al. 2013. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. Nicotine Tob. Res. 15:3718–28 https://doi.org/10.1093/ntr/nts186
    [Crossref] [Google Scholar]
  144. Taylor GMJ, Dalili MN, Semwal M, Civljak M, Sheikh A, Car J. 2017. Internet-based interventions for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD007078.pub5
    [Crossref] [Google Scholar]
  145. Tengs T, Adams M, Pliskin J, Safran D, Seigel J, Weinstein M. 1995. Five-hundred life-saving interventions and their cost effectiveness. Risk Anal 15:3369–90
     [Google Scholar]
  146. Tiffany ST. 1990. A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol. Rev. 97:2147–68
     [Google Scholar]
  147. Tindle HA, Greevy RA. 2018. Smoking cessation pharmacotherapy, even without counseling, remains a cornerstone of treatment. J. Natl. Cancer Inst. 110:6545–46 https://doi.org/10.1093/jnci/djx246
    [Crossref] [Google Scholar]
  148. Toll BA, O'Malley SS, Katulak NA, Wu R, Dubin JA et al. 2007. Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial. Psychol. Addict. Behav. 21:4534–44
     [Google Scholar]
  149. Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM et al. 2014.. “ Quitting smoking will benefit your health”: the evolution of clinician messaging to encourage tobacco cessation. Clin. Cancer Res. 20:2301–9 https://doi.org/10.1158/1078-0432.CCR-13-2261
    [Crossref] [Google Scholar]
  150. Tong EK, Stewart SL, Schillinger D, Vijayaraghavan M, Dove MS et al. 2018. The Medi-Cal Incentives to Quit Smoking Project: impact of statewide outreach through health channels. Am. J. Prev. Med. 55:6 Suppl. 2S159–69 https://doi.org/10.1016/j.amepre.2018.07.031
    [Crossref] [Google Scholar]
  151. US Dep. Health Hum. Serv 2016. E-cigarette use among youth and young adults: a report of the Surgeon General. Rep., US Dep. Health Hum. Serv. Rockville, MD: https://e-cigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf
  152. US Dep. Health Hum. Serv 2020. Smoking cessation: a report of the Surgeon General Rep., US Dep. Health Hum. Serv. Rockville, MD: https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf
  153. Vickerman KA, Keller PA, Deprey M, Lachter RB, Jenssen J, Dreher M. 2018. Never quit trying: reengaging tobacco users in statewide cessation services. J. Public Health Manag. Pract. 24:3e25–33
     [Google Scholar]
  154. Wampold BE. 2001. The Great Psychotherapy Debate: Model, Methods, and Findings Mahwah, NJ: Lawrence Erlbaum
  155. West R, Baker CL, Cappelleri JC, Bushmakin AG. 2008. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 197:371–77
     [Google Scholar]
  156. Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. 2016. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD006611.pub4
    [Crossref] [Google Scholar]
  157. Willett JG, Hood NE, Burns EK, Swetlick JL, Wilson SM et al. 2009. Clinical faxed referrals to a tobacco quitline: reach, enrollment, and participant characteristics. Am. J. Prev. Med. 36:4337–40 https://doi.org/10.1016/j.amepre.2008.12.004
    [Crossref] [Google Scholar]
  158. Wilson SJ, Creswell KG, Sayette MA, Fiez JA. 2013. Ambivalence about smoking and cue-elicited neural activity in quitting-motivated smokers faced with an opportunity to smoke. Addict. Behav. 38:21541–49 https://doi.org/10.1016/j.addbeh.2012.03.020
    [Crossref] [Google Scholar]
  159. Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M et al. 2003. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob. Res. 5:2245–54
     [Google Scholar]
  160. Xu X, Alexander RL Jr, Simpson SA, Goates S, Nonnemaker JM et al. 2015. A cost-effectiveness analysis of the first federally funded antismoking campaign. Am. J. Prev. Med. 48:3318–25 https://doi.org/10.1016/j.amepre.2014.10.011
    [Crossref] [Google Scholar]
  161. Ybarra ML, Jiang Y, Free C, Abroms LC, Whittaker R. 2016. Participant-level meta-analysis of mobile phone-based interventions for smoking cessation across different countries. Prev. Med. 89:90–97 https://doi.org/10.1016/j.ypmed.2016.05.002
    [Crossref] [Google Scholar]
  162. Yingst JM, Veldheer S, Hrabovsky S, Hammett E, Nicholson J et al. 2018. Pilot randomized trial of an automated smoking cessation intervention via mobile phone text messages as an adjunct to varenicline in primary care. J. Health Commun. 23:4370–78 https://doi.org/10.1080/10810730.2018.1453890
    [Crossref] [Google Scholar]
  163. Zelman DC, Brandon TH, Jorenby DE, Baker TB. 1992. Measures of affect and nicotine dependence predict differential response to smoking cessation treatments. J. Consult. Clin. Psychol. 60:6943–52
     [Google Scholar]
  164. Zhang B, Cohen JE, Bondy SJ, Selby P. 2015. Duration of nicotine replacement therapy use and smoking cessation: a population-based longitudinal study. Am. J. Epidemiol. 181:7513–20 https://doi.org/10.1093/aje/kwu292
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-081219-090343
Loading
Smoking Treatment: A Report Card on Progress and Challenges
Annual Review of Clinical Psychology 17, 1 (2021); https://doi.org/10.1146/annurev-clinpsy-081219-090343
/content/journals/10.1146/annurev-clinpsy-081219-090343
/content/journals/10.1146/annurev-clinpsy-081219-090343
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error